Goveas, Joseph S., Hogan, Patricia E., Kotchen, Jane M., Smoller, Jordan W., Denburg, Natalie L., Manson, JoAnn E., Tummala, Aruna, Mysiw, W. Jerry, Ockene, Judith K., Woods, Nancy F., Espeland, Mark A., Wassertheil-Smoller, Sylvia

Background: Antidepressants are commonly prescribed medications in the elderly, but their relationship with incident mild cognitive impairment (MCI) and probable dementia is unknown.; Methods: The study cohort included 6,998 cognitively healthy, postmenopausal women, aged 65-79 years, who were enrolled in a hormone therapy clinical trial and had baseline depressive symptoms and antidepressant use history assessments […]

Eggermont, Laura H.P., de Vries, Kerst, Scherder, Erik J.A.

Background: Most studies examining psychotropic medication use on cognition in older persons with dementia include measures of global cognitive function. The present study examined the relationship between different types of psychotropic medication and specific cognitive functions in older people with dementia.; Methods: Two hundred and six institutionalized older adults with dementia (180 women, mean age […]

Pelton, Gregory H., Andrews, Howard, Roose, Steven P., Marcus, Sue M., D'Antonio, Kristina, Husn, Hala, Petrella, Jeffrey R., Zannas, Anthony S., Doraiswamy, P. Murali, Devanand, D. P.

Treatment strategies for patients with depression and cognitive impairment (DEP-CI), who are at high risk to develop a clinical diagnosis of dementia, are not established. This issue is addressed in the donepezil treatment of cognitive impairment and depression (DOTCODE) pilot clinical trial. The DOTCODE study is the first long-term treatment trial that assesses differences in […]

Flynn Longmire, Crystal V., Drye, Lea T., Frangakis, Constantine E., Martin, Barbara K., Meinert, Curtis L., Mintzer, Jacobo E., Munro, Cynthia A., Porsteinsson, Anton P., Rabins, Peter V., Rosenberg, Paul B., Schneider, Lon S., Weintraub, Daniel, Lyketsos, Constantine G.

Objective: We wanted to assess if sertraline treatment (versus placebo) or remission of depression at 12 weeks (versus nonremission) in Alzheimer patients is associated with improved caregiver well being.; Methods: We conducted a randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of sertraline for the treatment of depression in individuals with Alzheimer disease […]